Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 30;11(8):e007202. doi: 10.1136/jitc-2023-007202

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Combinatory effect of HLA-B-21 dimorphism and NKG2A gene variants on granzyme B levels and clinical outcome of IL-2 based therapy in AML patients. (A–D) Impact of NKG2A SNP alleles on granzyme-B load of CD16⁺ CD56^dim NK cells in AML patients at the beginning and after one course of IL-2 based therapy in HLA-B-21 TT carriers (A, B) and HLA-B-21 M/x carriers (C, D). (E) Leukemia-free survival for patients with NKG2A GG (n=11) or C/x (n=31) in patients with an HLA-B –21 TT genotype. (F) Leukemia-free survival for HLA-B –21 M/x patients dichotomized into NKG2A GG (n=16) and C/x (n=21). AML, acute myeloid leukemia; LFS, leukemia-free survival; NK, natural killer.